The global biopsy devices market, valued at USD 7.27 billion in 2024, is projected to reach USD 11.01 billion by 2030, growing at a CAGR of 7.2%. Biopsy devices play a pivotal role in modern diagnostics, allowing clinicians to extract tissue samples for identifying cancer, infections, and other pathological conditions. The growing demand for early cancer detection, rising global cancer prevalence, and technological advancements in imaging-guided and robotic biopsy systems are accelerating market expansion across hospitals and diagnostic centers.
Rising Cancer Incidence and Early Diagnosis Awareness Fuel Market Growth
The increasing global burden of cancer remains the primary growth engine for the biopsy devices industry. According to WHO, cancer is responsible for nearly 10 million deaths annually, making it one of the leading causes of mortality worldwide. This growing incidence is pushing healthcare systems and governments to strengthen screening programs, particularly for breast, lung, and prostate cancers—conditions where biopsies are the gold standard for diagnosis.
Additionally, awareness campaigns promoting early cancer screening and timely diagnosis have surged. Organizations such as the American Cancer Society and European Cancer Organization continue to emphasize early-stage detection through advanced biopsy technologies. The growing adoption of minimally invasive and image-guided biopsy techniques, such as stereotactic and ultrasound-guided biopsies, enables clinicians to improve diagnostic accuracy while reducing patient discomfort.
However, market expansion is tempered by high procedural costs and limited access to advanced devices in developing economies. Many healthcare systems, especially in low- and middle-income regions, struggle to afford state-of-the-art biopsy systems due to infrastructure and reimbursement challenges.
By Product: Biopsy Accessories Secure a Solid Market Position
The biopsy accessories segment holds the second-largest market share within the biopsy devices market. Biopsy accessories include needles, forceps, localization wires, and other essential instruments used to ensure sample precision and procedural success. Their consistent use across various biopsy methods and their critical role in ensuring diagnostic reliability make them indispensable to healthcare providers.
Continuous innovation in disposable and minimally invasive accessories is reshaping this segment. Manufacturers are developing eco-friendly disposable biopsy tools that reduce infection risks and improve procedural efficiency. Furthermore, the adoption of robotic-assisted systems is increasing demand for compatible, precision-engineered accessories that enhance the overall accuracy of biopsy sampling.
Hospitals and diagnostic imaging centers continue to prioritize high-quality accessories that support AI-integrated biopsy systems. This trend highlights the increasing emphasis on data-driven precision in pathology, ensuring better tissue targeting and diagnostic yield.
By Technology: Imaging and AI Integration Transform the Biopsy Landscape
Biopsy technologies are rapidly evolving from conventional manual approaches to highly sophisticated image-guided and robotic-assisted platforms. Ultrasound and stereotactic biopsy technologies are gaining significant traction due to their real-time visualization capabilities and accuracy in targeting lesions. These methods allow clinicians to perform procedures with greater confidence and minimal patient trauma.
Recent advancements in AI-powered imaging are enhancing biopsy precision. Artificial intelligence assists in lesion identification, procedural planning, and automated sample tracking—optimizing both workflow and clinical outcomes. Moreover, 3D imaging systems and computer-assisted navigation are increasingly used for complex biopsies, particularly in oncology and neurology, reducing false negatives and improving diagnostic accuracy.
By End User: Hospitals & Breast Care Centers Lead Global Adoption
Based on end-user segmentation, hospitals and breast care centers dominate the biopsy devices market, holding the largest share in 2023. This leadership is supported by hospitals’ superior infrastructure, skilled medical professionals, and access to advanced imaging modalities such as MRI, CT, and digital mammography.
Breast care centers, in particular, are central to global cancer screening initiatives, especially as breast cancer remains the most diagnosed cancer worldwide. These facilities often collaborate with diagnostic laboratories and academic institutions, integrating biopsy procedures with molecular pathology and genomic testing for precision oncology.
Moreover, favorable reimbursement policies and insurance coverage for biopsy procedures—especially in North America and Europe—further bolster hospital-based adoption. The growing use of outpatient biopsy procedures in ambulatory surgical centers also reflects the industry’s shift toward minimally invasive, cost-efficient healthcare delivery.
Regional Insights: North America Dominates, Asia Pacific Shows Strong Growth Potential
North America continues to dominate the global biopsy devices market, accounting for 32.9% of total market share in 2023. The region’s dominance is underpinned by its advanced healthcare infrastructure, high cancer prevalence, and early adoption of cutting-edge biopsy technologies. The presence of leading market players such as BD (US), Hologic (US), and Boston Scientific (US) ensures a strong innovation pipeline and continuous product launches.
Government support for cancer research funding, combined with favorable reimbursement policies, further accelerates market penetration. Additionally, the region’s aging population contributes significantly to demand, as older individuals are more prone to cancer and chronic diseases requiring biopsy-based diagnosis.
Meanwhile, the Asia Pacific region is emerging as a high-growth market due to rising healthcare investments, expanding medical infrastructure, and increasing cancer screening awareness. Countries such as China, India, and Japan are witnessing rapid adoption of biopsy technologies, driven by both government initiatives and private sector healthcare expansion.
Competitive Landscape: Innovation and Strategic Partnerships Define the Market
The biopsy devices market is highly competitive, with key players focusing on technological innovation, product portfolio expansion, and strategic collaborations. Major players include:
BD (US), Devicor Medical Products (US), Medtronic (Ireland), Cardinal Health (US), B. Braun SE (Germany), Hologic, Inc. (US), Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Corporation (Japan), Stryker (US), Teleflex Incorporated (US), CONMED Corporation (US), Merit Medical Systems (US), Johnson & Johnson Services (US), Cook Group (US), MicroPort Scientific (China), Argon Medical Devices (US), and Trivitron Healthcare (India).
These companies are investing heavily in AI-driven biopsy navigation systems, robotic precision tools, and minimally invasive disposable instruments to strengthen their global footprint. Mergers and acquisitions are also shaping market dynamics, enabling firms to expand their technology base and reach untapped geographies.
Conclusion: Toward Precision Diagnostics and Patient-Centered Care
The global biopsy devices market is evolving rapidly, driven by technological innovation, rising cancer awareness, and increasing healthcare accessibility. As the industry embraces AI, robotics, and personalized diagnostics, biopsy procedures are becoming more efficient, accurate, and patient-friendly.
Looking ahead to 2030, the integration of digital pathology, real-time data analytics, and remote diagnostic capabilities will redefine how biopsies are performed and interpreted—ushering in a new era of precision-driven, minimally invasive diagnostics that promise better outcomes and global accessibility.